NCT02681302: An ongoing trial by Hackensack Meridian Health
This trial is ongoing. It must report results 1 month, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02681302 |
|---|---|
| Title | Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 7, 2016 |
| Completion date | May 10, 2024 |
| Required reporting date | May 10, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |